Deadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP announced a class action lawsuit against Replimune Group, Inc. for alleged securities fraud. The company made misleading statements about its FDA drug application (RP1 BLA) between October 2025 and April 2026. The FDA rejected the application on April 10, 2026, citing undisclosed study design deficiencies and insufficient patient data (40 of 400 planned patients), causing the stock to plummet 19.46% on the day and an additional 64.29% decline by April 13, 2026. Investors who purchased shares during the class period are urged to file lead plaintiff motions by October 5, 2026.